Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

299,921 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality.
Rejeski K, Wang Y, Hansen DK, Iacoboni G, Bachy E, Bansal R, Penack O, Müller F, Bethge W, Munoz J, Mohty R, Bücklein VL, Barba P, Locke FL, Lin Y, Jain MD, Subklewe M. Rejeski K, et al. Among authors: wang y. Blood Adv. 2024 Apr 23;8(8):1857-1868. doi: 10.1182/bloodadvances.2023011767. Blood Adv. 2024. PMID: 38181508 Free PMC article.
The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel.
Wudhikarn K, Bansal R, Khurana A, Hathcock MA, Bennani NN, Paludo J, Villasboas JC, Wang Y, Johnston PB, Ansell SM, Lin Y. Wudhikarn K, et al. Among authors: wang y. Blood Cancer J. 2021 Jul 1;11(7):124. doi: 10.1038/s41408-021-00515-2. Blood Cancer J. 2021. PMID: 34210955 Free PMC article. No abstract available.
Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel.
Wudhikarn K, Bansal R, Khurana A, Hathcock MA, Braksick SA, Bennani NN, Paludo J, Villasboas JC, Wang Y, Johnston PB, Ansell SM, Lin Y. Wudhikarn K, et al. Among authors: wang y. Am J Hematol. 2021 Nov 1;96(11):E427-E430. doi: 10.1002/ajh.26330. Epub 2021 Sep 7. Am J Hematol. 2021. PMID: 34424554 Free article. No abstract available.
Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?
Saifi O, Breen WG, Lester SC, Rule WG, Stish B, Rosenthal A, Munoz J, Herchko SM, Murthy HS, Lin Y, Bansal R, Hathcock MA, Bennani NN, Paludo J, Wang Y, Khurana A, Bisneto JCV, Johnston PB, Ansell SM, Iqbal M, Tun H, Ayala E, Kharfan-Dabaja MA, Hoppe BS, Peterson JL. Saifi O, et al. Among authors: wang y. Radiother Oncol. 2022 Jan;166:171-179. doi: 10.1016/j.radonc.2021.11.031. Epub 2021 Dec 7. Radiother Oncol. 2022. PMID: 34890736 Free article.
Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT.
Breen WG, Hathcock MA, Young JR, Kowalchuk RO, Bansal R, Khurana A, Bennani NN, Paludo J, Villasboas Bisneto JC, Wang Y, Ansell SM, Peterson JL, Johnston PB, Lester SC, Lin Y. Breen WG, et al. Among authors: wang y. J Hematol Oncol. 2022 Mar 26;15(1):36. doi: 10.1186/s13045-022-01256-w. J Hematol Oncol. 2022. PMID: 35346315 Free PMC article.
Peak absolute lymphocyte count after CAR-T infusion predicts clinical response in aggressive lymphoma.
Bansal R, Novo M, Al Saleh AS, Guerrico AG, Zhang H, Shao Z, Babadi E, Martinez KE, McCoy GA, Hathcock MA, Khurana A, Bennani NN, Paludo J, Wang Y, Ansell SM, Johnston PB, Villasboas JC, Lin Y. Bansal R, et al. Among authors: wang y. Am J Hematol. 2022 Jul;97(7):E241-E244. doi: 10.1002/ajh.26561. Epub 2022 Apr 14. Am J Hematol. 2022. PMID: 35385152 Free article. No abstract available.
Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
Muñoz J, Wang Y, Jain P, Wang M. Muñoz J, et al. Among authors: wang y, wang m. Ther Adv Hematol. 2022 May 27;13:20406207221093980. doi: 10.1177/20406207221093980. eCollection 2022. Ther Adv Hematol. 2022. PMID: 35651781 Free PMC article. Review.
Incidence and Risk Factors for Acute Kidney Injury After Chimeric Antigen Receptor T-Cell Therapy.
Farooqui N, Sy-Go JPT, Miao J, Mehta R, Vaughan LE, Bennani NN, Wang Y, Bansal R, Hathcock MA, Hayman SR, Johnston PB, Villasboas JC, Paludo J, Ansell SM, Leung N, Lin Y, Herrmann SM. Farooqui N, et al. Among authors: wang y. Mayo Clin Proc. 2022 Jul;97(7):1294-1304. doi: 10.1016/j.mayocp.2022.05.018. Mayo Clin Proc. 2022. PMID: 35787856 Free PMC article.
299,921 results
You have reached the last available page of results. Please see the User Guide for more information.